A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Hematologic response (complete hematologic response (CHR) / no evidence of leukemia (NEL) / return to chronic phase (RTC)) rate assessed by a blood test
throughout the study
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
CLBH589B2211
NCT00449761
February 2007
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
Roswell Park Cancer Institute | Buffalo, New York 14263 |
Mayo Clinic Cancer Center | Rochester, Minnesota 55905 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
University of Rochester Medical Center | Rochester, New York 14642 |
Rocky Mountain Cancer Center | Denver, Colorado 80218 |
City of Hope National Medical Center | Los Angeles, California 91010 |
Seattle Cancer Care Alliance | Seattle, Washington 98109 |
Oregon Health & Science University | Portland, Oregon 97201 |
University of Texas Southwestern Medical Center | Dallas, Texas |
Wake Forest University Health Sciences | Winston-Salem, North Carolina 27157 |
Duke University Hospital | Durham, North Carolina 27710 |
University Chicago Hospital | Chicago, Illinois 60637 |
University of Colorado Health Sciences Center/Anschutz Cancer Pavilion | Aurora, Colorado 80010 |
Northwestern University Clinical Research Office | Chicago, Illinois 60611 |
Indiana Blood and Marrow Institute/St. Francis Hospital | Beech Grove, Indiana 46107 |
Hackensack University Medical Center/Oncology Research Dept. | Hackensack, New Jersey 07601 |
Emory University School of Medicine-Winship Cancer Institute | Nashville, Tennessee 37212 |
Vanderbilt University Medical Center, Clinical Trials Center | Nashville, Tennessee 37212 |